Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

Psoriasis is a typical chronic inflammatory disease. Typical symptoms are thick plates of silvery white keratin that usually ...

Icotrokinra, formerly known as JNJ-2113, is an investigational oral peptide that blocks the interleukin (IL)-23 receptor, which plays a significant role in the pathogenesis of moderate to severe ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Endo, Inc. (OTCQX: NDOI) has reached a definitive agreement with MC2 Therapeutics to commercialize Wynzora® Cream in Canada ...

Additionally, it can also be caused by multiple rounds of chemotherapy, and depression treatment drugs. The spleen is essential for filtering blood, supporting immune function, and managing red blood ...

Top-line results show that 64.7% of patients achieved clear or almost clear skin measured using the Investigator's Global ...

Protagonist Therapeutics (PTGX) announced positive topline results from its collaboration with Johnson & Johnson (JNJ), in ICONIC-LEAD1 and ...

The "Plaque Psoriasis: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.The analyst estimates that sales of drugs in the Plaque Psoriasis (PsO) market ...

Discover why analysts are bullish on Arcutis Biotherapeutics after strong Q3 results, despite recent market fluctuations in ...

Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition - - Continued to advance three clinical programs ...

MALVERN, Pa., Nov. 15, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI ) announced today that it has entered into a definitive agreement with MC2 Therapeutics ("MC2") to commercialize Wynzora® Cream ...